1
|
Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande Pulido E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E. O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
2
|
Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021; 21:597. [PMID: 34030646 PMCID: PMC8146685 DOI: 10.1186/s12885-021-08306-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 05/05/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND & AIMS Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous neoplasms. Although some have a relatively benign and indolent natural history, others can be aggressive and ultimately fatal. Somatostatin analogues (SSAs) improve both quality of life and survival for these patients once they develop metastatic disease. However, these drugs are costly and their cost-effectiveness is not known. METHODS A decision-analytic model was developed and analyzed to compare two treatment strategies for patients with Stage IV GEP-NETs. The first strategy had all patients start SSA immediately while the second strategy waited, reserving SSA initiation until the patient showed signs of progression. Sensitivity analysis was performed to explore model parameter uncertainty. RESULTS Our model of patients age 60 with metastatic GEP-NETs suggests empiric initiation of SSA led to an increase 0.62 unadjusted life-years and incremental increase in quality-adjusted life years (QALYs) of 0.44. The incremental costs were $388,966 per QALY and not cost-effective at a willingness-to-pay threshold of $100,000. Death was attributed to GEP-NETs for 94.1% of patients in the SSA arm vs. 94.9% of patients in the DELAY SSA arm. Sensitivity analysis found that the model was most sensitive to costs of SSAs. Using probabilistic sensitivity analysis, the SSA strategy was only cost-effective 1.4% of the time at a WTP threshold of $100,000 per QALY. CONCLUSIONS Our modeling study finds it is not cost-effective to initiate SSAs at time of presentation for patients with metastatic GEP-NETs. Further clinical studies are needed to identify the optimal timing to initiate these drugs.
Collapse
Affiliation(s)
- Sheila D Rustgi
- Henry D. Janowitz Division of Gastroenterology, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1118, New York, NY, 10029-6574, USA
- Columbia University Irving Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Aaron Oh
- Columbia University Irving Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Jeong Yun Yang
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Dasol Kang
- Department of Internal Medicine, Lincoln Medical Center, Bronx, NY, USA
| | - Edward Wolin
- Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Chung Y Kong
- Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Chin Hur
- Columbia University Irving Cancer Center, Columbia University Medical Center, New York, NY, USA
| | - Michelle K Kim
- Henry D. Janowitz Division of Gastroenterology, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1118, New York, NY, 10029-6574, USA.
| |
Collapse
|
3
|
Kessel E, Naparst M, Alpert N, Diaz K, Ahn E, Wolin E, Taioli E, Kim MK. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States. Pancreas 2021; 50:29-36. [PMID: 33370020 DOI: 10.1097/mpa.0000000000001707] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
OBJECTIVES The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. METHODS Using the Surveillance, Epidemiology, and End Results Registry, we identified patients with GEP-NETs of the stomach, small intestine (SI), colon, rectum, appendix, and pancreas diagnosed between 1973 and 2014. Demographic, cancer, and treatment information were collected and compared using χ2 tests. Multivariable logistic and Cox regression were used to determine disparities in receiving treatment and overall survival. RESULTS We identified 19,031 GEP-NET patients: 2839 were non-Hispanic Blacks, 12,832 non-Hispanic Whites, 2098 Hispanics, and 1262 Asians. African Americans and Hispanics with SI and pancreatic NETs were less likely to be treated with surgery (odds ratio, 0.6; 95% confidence interval [CI], 0.46-0.69; odds ratio, 0.71; 95% CI, 0.51-0.99, respectively). African American race was not an independent predictor of survival; there was a strong trend in stomach, SI, and pancreas NETs (hazard ratio [HR], 1.31; 95% CI, 1-1.7; HR, 1.2; 95% CI, 0.99-1.45; HR, 1.22; 95% CI, 1-1.48, respectively). CONCLUSIONS Our study provides evidence of racial disparities in treatment and survival across GEP-NET primary sites and racial groups. Further studies should be performed to improve our understanding of the reason for these disparities.
Collapse
Affiliation(s)
- Elizabeth Kessel
- From the Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York
| | | | - Naomi Alpert
- Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Kelly Diaz
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA
| | - Eugene Ahn
- Sophie Davis Biomedical Education Program, CUNY School of Medicine
| | - Edward Wolin
- Department of Oncology, Icahn School of Medicine at Mount Sinai
| | | | - Michelle Kang Kim
- From the Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York
| |
Collapse
|
4
|
Lombard-Bohas C, Cao CD, Metges JP, Philippe Ruszniewski, Smith D, Guimbaud R, Lepage C, Ron Hollander, Goldstein G, Wolin E, Santos A, Baudin E. French patient-reported experience of diagnosis, management and burden of neuroendocrine tumors. International Journal of Endocrine Oncology 2020. [DOI: 10.2217/ije-2020-0013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Background: There is a lack of knowledge regarding the experience of patients with neuroendocrine tumors (NET) in France. Materials & methods: A patient survey that captured information on diagnosis, disease impact/management and awareness was conducted. Data of respondents from France were analyzed and compared with US data as a reference. Results: Key topics included delays in diagnosis, negative impact on quality of life, patient access to NET medical experts and treatments, and information on NET and treatments. Significant differences were observed between France and the USA regarding NET diagnosis. Conclusion: This survey highlights the considerable burden experienced by patients in France with NET and differences in patient experience between France and the USA that may result from different healthcare and social systems.
Collapse
Affiliation(s)
| | - Christine Do Cao
- Centre Hospitalier Universitaire de Lille, Service Endocrinologie, Lille, France
| | - Jean-Philippe Metges
- Centre Hospitalier Régional Universitaire de Brest, Pôle Régional de Cancérologie, Brest, France
| | - Philippe Ruszniewski
- Université de Paris et Service de Pancréatologie, Hôpital Beaujon, Clichy, France
| | - Denis Smith
- Centre Hospitalier Universitaire de Bordeaux, Service d'Oncologie Médicale, Bordeaux, France
| | - Rosine Guimbaud
- Centre Hospitalier Universitaire de Toulouse, Service d'Oncologie Médicale, Toulouse, France
| | | | - Ron Hollander
- International Neuroendocrine Cancer Alliance (INCA), Newton, MA, USA
| | | | - Edward Wolin
- Center for Carcinoid and Neuroendocrine Tumors, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | | | - Eric Baudin
- Institute Gustave Roussy, Service de Médecine Nucléaire, Villejuif, France
| |
Collapse
|
5
|
Khetan P, Oyewole F, Wolin E, Kim MK, Divino CM. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center. Pancreas 2020; 49:509-513. [PMID: 32224719 DOI: 10.1097/mpa.0000000000001520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
OBJECTIVES Neuroendocrine tumors represent approximately 40% of primary small bowel malignancies. However, factors predictive of progression after multimodal surgical therapy have not been well described. We evaluated the characteristics of small bowel neuroendocrine tumor patients associated with progression after multimodal surgical resection. METHODS A retrospective chart review identified 99 stage III and stage IV small bowel neuroendocrine tumor patients at Mount Sinai diagnosed and treated with surgery between 2005 and 2019. Progression-free survival (PFS) was defined as time from surgery until progression in surveillance radiologic imaging. Kaplan-Meier method was used to calculate PFS. Cox proportional hazard models were used to study the prognostic factors for PFS. RESULTS Of 99 patients, 48 had tumor progression during the follow-up period. Median PFS was 5.7 years (95% confidence interval [CI], 3.73-8.66) for the entire cohort. Prognostic factors for PFS were age at diagnosis (hazard ratio [HR], 1.04; 95% CI, 1.01-1.07), perineural invasion (HR, 2.19; 95% CI, 1.13-4.23), and elevated preoperative chromogranin level (HR, 2.31; 95% CI, 1.01-5.27). CONCLUSIONS Age at diagnosis, perineural invasion, and elevated preoperative chromogranin level may play a prognostic role in PFS.
Collapse
Affiliation(s)
- Prerna Khetan
- From the Departments of Surgery, Icahn School of Medicine
| | - Femi Oyewole
- From the Departments of Surgery, Icahn School of Medicine
| | | | | | | |
Collapse
|
6
|
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging 2020; 47:2372-2382. [PMID: 32123969 PMCID: PMC7396396 DOI: 10.1007/s00259-020-04709-x] [Citation(s) in RCA: 66] [Impact Index Per Article: 16.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 01/28/2020] [Indexed: 12/20/2022]
Abstract
PURPOSE To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. METHODS In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. RESULTS Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low (< 25%), moderate (25-50%), and high (> 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. CONCLUSIONS 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11.
Collapse
Affiliation(s)
- Jonathan Strosberg
- Gastrointestinal Department/Neuroendocrine Tumor Division, Moffitt Cancer Center, Tampa, FL, USA.
| | - Pamela L Kunz
- Department of Medicine - Med/Oncology, Stanford University Medical Center, Stanford, CA, USA
| | - Andrew Hendifar
- Department of Internal Medicine/Hematology/Oncology, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - James Yao
- Department of Gastrointestinal Medicinal Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - David Bushnell
- Department of Radiology, The University of Iowa, Iowa City, IA, USA
| | - Matthew H Kulke
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Richard P Baum
- Department of Nuclear Medicine, Zentralklinik Bad Berka, Bad Berka, Germany
| | - Martyn Caplin
- Department of Gastroenterology and Tumour Neuroendocrinology, Royal Free Hospital, London, UK
| | | | - Ebrahim Delpassand
- Department of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, TX, USA
| | - Timothy Hobday
- Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
| | - Chris Verslype
- Department of Hepatology, University Hospitals and KU Leuven, Leuven, Belgium
| | - Al Benson
- Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
| | - Rajaventhan Srirajaskanthan
- Department of Gastroenterology and General Internal Medicine, King's College Hospital - NHS Foundation Trust, London, UK
| | - Marianne Pavel
- Division of Hepatology and Gastroenterology, Charite-Universitätsmedizin Berlin, Berlin, Germany
| | - Jaume Mora
- Department of Nuclear Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain
| | - Jordan Berlin
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Enrique Grande
- Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | - Nicholas Reed
- Department of Medical Oncology, Beatson Oncology Centre, Glasgow, UK
| | - Ettore Seregni
- Department of Nuclear Medicine Therapy and Endocrinology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy
| | - Giovanni Paganelli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Stefano Severi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Michael Morse
- Department of Surgery, Duke University Medical Center, Durham, NC, USA
| | - David C Metz
- GI Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
| | - Catherine Ansquer
- Nuclear Medicine Department, Hôtel Dieu, University Hospital, Nantes, France
| | - Frédéric Courbon
- Medical Imaging, Oncology University Institut Claudius Regaud, Toulouse, France
| | - Adil Al-Nahhas
- Division of Imaging and Interventional Radiology, Imperial College London, London, UK
| | - Eric Baudin
- Department of Endocrine Oncology and Nuclear Medicine, Institut Gustave Roussy, Villejuif, France
| | - Francesco Giammarile
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - David Taïeb
- Department of Nuclear Medicine, Hôpital de la Timone, Marseille, France
| | - Erik Mittra
- Department of Nuclear Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Edward Wolin
- Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas M O'Dorisio
- Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA
| | - Rachida Lebtahi
- Department of Nuclear Medicine, Royal Free Hospital, London, UK
| | - Christophe M Deroose
- Nuclear Medicine Department, University Hospitals and KU Leuven, Leuven, Belgium
| | - Chiara M Grana
- Division of Nuclear Medicine, Istituto Europeo di Oncologia, Milan, Italy
| | - Lisa Bodei
- Department of Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Kjell Öberg
- Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
| | - Berna Degirmenci Polack
- Department of Medical Information, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Beilei He
- Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Maurizio F Mariani
- Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Germo Gericke
- Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Paola Santoro
- Department of Clinical Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Jack L Erion
- Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Laura Ravasi
- Research and Development, Advanced Accelerator Applications, a Novartis Company, Geneva, Switzerland
| | - Eric Krenning
- Department of Nuclear Medicine, Cyclotron Rotterdam BV, Erasmus University Medical Center, Rotterdam, Netherlands
| | | |
Collapse
|
7
|
Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M. A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. PLoS One 2019; 14:e0221994. [PMID: 31527867 PMCID: PMC6748410 DOI: 10.1371/journal.pone.0221994] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Accepted: 07/20/2019] [Indexed: 02/07/2023] Open
Abstract
Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET).Enrolled patients had metastatic, well-differentiated NET of non-pancreatic gastrointestinal or unknown origin, with/without carcinoid symptoms, had failed ≥1 systemic chemotherapy, and were taking a somatostatin analog (SSA). Oral once-daily CC-223 was administered in 28-day cycles starting at 45 mg (n = 24), with a subsequent cohort starting at 30 mg (n = 23). Objectives were to evaluate tolerability, preliminary efficacy, and pharmacokinetic and biomarker profiles of CC-223. Forty-seven patients completed the study, with mean treatment duration of 378 days and mean dose of 26 mg; 26% of patients remained on the starting dose. Most frequent grade ≥3 toxicities were diarrhea (38%), fatigue (21%), and stomatitis (11%). By investigator, 3 of 41 evaluable patients (7%) showed partial response (PR) and 34 (83%) had stable disease (SD) for a disease control rate (DCR) of 90% (95% confidence interval [CI] 76.9–97.3%). Duration of PR was 125–401 days; median SD duration was 297 days (min–max, 50–1519 days). Median progression-free survival was 19.5 months (95% CI 10.4–28.5 months). Carcinoid symptoms of flushing, diarrhea, or both improved in 50%, 41%, and 39% of affected patients, respectively. For the first time, this study describes that a second-generation mTOR pathway inhibitor can result in highly durable tumor regression and control of NET carcinoid symptoms. The manageable safety profile, high DCR, and durable response, coupled with reduction in carcinoid symptoms refractory to SSA, make CC-223 a promising agent for further development.
Collapse
Affiliation(s)
- Edward Wolin
- Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America
- * E-mail:
| | - Alain Mita
- Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America
| | - Amit Mahipal
- Phase 1 Clinical Trials Program, Mayo Clinic, Rochester, MN, United States of America
| | - Tim Meyer
- Experimental Cancer Medicine, University College Hospital, London, United Kingdom
| | - Johanna Bendell
- GI Oncology Research, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, United States of America
| | - John Nemunaitis
- Department of Oncology, Mary Crowley Cancer Research Center, Dallas, TX, United States of America
| | - Pam N. Munster
- Early Phase Clinical Research Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States of America
| | - Luis Paz-Ares
- Medical Oncology Department, Hospital Universitario 12 de Octubre, CNIO, Universidad Complutense and CiberOnc, Madrid, Spain
| | - Ellen H. Filvaroff
- Translational Medicine, Celgene Corporation, San Francisco, CA, United States of America
| | - Shaoyi Li
- Department of Statistics, Celgene Corporation, Summit, NJ, United States of America
| | - Kristen Hege
- Translational Medicine, Celgene Corporation, San Francisco, CA, United States of America
| | - Hans de Haan
- Translational Medicine, Celgene Corporation, San Francisco, CA, United States of America
| | - Monica Mita
- Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America
| |
Collapse
|
8
|
Strosberg J, Hendifar A, Yao J, Kulke M, O’Dorisio T, Caplin M, Baum R, Kunz P, Hobday T, Wolin E, Mittra E, Oberg K, Ruszniewski P, Polack B, He B, Barton D, Santaro P, Krenning E. Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy293.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 2018; 36:2578-2584. [PMID: 29878866 DOI: 10.1200/jco.2018.78.5865] [Citation(s) in RCA: 226] [Impact Index Per Article: 37.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related QoL. Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with 177Lu-Dotatate versus high-dose octreotide. European Organisation for Research and Treatment of Cancer quality-of-life questionnaires QLQ C-30 and G.I.NET-21 were assessed during the trial to determine the impact of treatment on health-related QoL. Patients completed the questionnaires at baseline and every 12 weeks until tumor progression. QoL scores were converted to a 100-point scale according to European Organisation for Research and Treatment of Cancer instructions, and individual changes from baseline scores were assessed. Time to QoL deterioration (TTD) was defined as the time from random assignment to the first QoL deterioration ≥ 10 points for each patient in the corresponding domain scale. All analyses were conducted on the intention-to-treat population. Patients with no deterioration were censored at the last QoL assessment date. Results TTD was significantly longer in the 177Lu-Dotatate arm (n = 117) versus the control arm (n = 114) for the following domains: global health status (hazard ratio [HR], 0.406), physical functioning (HR, 0.518), role functioning (HR, 0.580), fatigue (HR, 0.621), pain (HR, 0.566), diarrhea (HR, 0.473), disease-related worries (HR, 0.572), and body image (HR, 0.425). Differences in median TTD were clinically significant in several domains: 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning. Conclusion This analysis from the NETTER-1 phase III study demonstrates that, in addition to improving progression-free survival, 177Lu-Dotatate provides a significant QoL benefit for patients with progressive midgut NETs compared with high-dose octreotide.
Collapse
Affiliation(s)
- Jonathan Strosberg
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Edward Wolin
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Beth Chasen
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Matthew Kulke
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - David Bushnell
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Martyn Caplin
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Richard P Baum
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Pamela Kunz
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Timothy Hobday
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Andrew Hendifar
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Kjell Oberg
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Maribel Lopera Sierra
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Thomas Thevenet
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Ines Margalet
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Philippe Ruszniewski
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | - Eric Krenning
- Jonathan Strosberg, Moffitt Cancer Center, Tampa, FL; Edward Wolin, Montefiore Einstein Center for Cancer Care, Bronx, NY; Beth Chasen, University of Texas MD Anderson Cancer Center, Houston, TX; Matthew Kulke, Dana-Farber Cancer Institute, Boston, MA; David Bushnell, University of Iowa, Iowa City, IA; Martyn Caplin, Royal Free Hospital, London, United Kingdom; Richard P. Baum, Zentralklinik, Bad Berka, Germany; Pamela Kunz, Stanford University Medical Center, Stanford; Andrew Hendifar, Cedars Sinai Medical Center, Los Angeles, CA; Timothy Hobday, Mayo Clinic College of Medicine, Rochester, MN; Kjell Oberg, University Hospital, Uppsala University, Uppsala, Sweden; Maribel Lopera Sierra, Thomas Thevenet, and Ines Margalet, Advanced Accelerator Applications, Geneva, Switzerland; Philippe Ruszniewski, Hopital Beaujon and Paris Diderot University, Clichy, France; and Eric Krenning, Erasmus Medical Center, Rotterdam, Netherlands
| | | |
Collapse
|
10
|
Thanh XMT, Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D, Hoersch D, Houchard A, Caplin M, Baudin E. 232TiP Lanreotide autogel/depot in lung neuroendocrine tumours: The randomized, double-blind, placebo-controlled, international phase 3 SPINET Study. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30504-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology 2018; 106:211-220. [PMID: 28554173 DOI: 10.1159/000477585] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 05/18/2017] [Indexed: 11/19/2022]
Abstract
PURPOSE The RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin. METHODS Patients in the RADIANT-4 trial were randomized 2:1 to everolimus 10 mg/day or placebo. The effect of everolimus on PFS was evaluated in patients with NET of the GI tract or unknown primary site. RESULTS Of the 302 patients enrolled, 175 had GI NET (everolimus, 118; placebo, 57) and 36 had unknown primary (everolimus, 23; placebo, 13). In the GI subset, the median PFS by central review was 13.1 months (95% CI 9.2-17.3) in the everolimus arm versus 5.4 months (95% CI 3.6-9.3) in the placebo arm; the hazard ratio (HR) was 0.56 (95% CI 0.37-0.84). In the unknown primary patients, the median PFS was 13.6 months (95% CI 4.1-not evaluable) for everolimus versus 7.5 months (95% CI 1.9-18.5) for placebo; the HR was 0.60 (95% CI 0.24-1.51). Everolimus efficacy was also demonstrated in both midgut and non-midgut populations; a 40-46% reduction in the risk of progression or death was reported for patients in the combined GI and unknown primary subgroup. Everolimus had a benefit regardless of prior somatostatin analog therapy. CONCLUSIONS Everolimus showed a clinically meaningful PFS benefit in patients with advanced progressive nonfunctional NET of GI and unknown primary, consistent with the overall RADIANT-4 results, providing an effective new standard treatment option in this patient population and filling an unmet treatment need for these patients.
Collapse
Affiliation(s)
- Simron Singh
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci 2017; 109:174-181. [PMID: 29055056 PMCID: PMC5765303 DOI: 10.1111/cas.13427] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Revised: 10/11/2017] [Accepted: 10/16/2017] [Indexed: 12/23/2022] Open
Abstract
In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best supportive care. This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures. Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n = 63; placebo, n = 27). Median PFS (95% CI) by central review was 9.2 (6.8-10.9) months in the everolimus arm vs 3.6 (1.9-5.1) months in the placebo arm (hazard ratio, 0.50; 95% CI, 0.28-0.88). More patients who received everolimus (58%) experienced tumor shrinkage compared with placebo (13%). Most frequently reported (≥5% incidence) grade 3-4 drug-related adverse events (everolimus vs. placebo) included stomatitis (11% vs. 0%), hyperglycemia (10% vs. 0%), and any infections (8% vs. 0%). In patients with advanced, progressive, well-differentiated, non-functional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 cohort. These results support the use of everolimus in patients with advanced, non-functional lung NET. The trial is registered with ClinicalTrials.gov (no. NCT01524783).
Collapse
Affiliation(s)
- Nicola Fazio
- European Institute of Oncology, IRCCS, Milan, Italy
| | - Roberto Buzzoni
- Fondazione IRCCS Foundation, The National Institute of Tumors, Milan, Italy
| | | | - Margot E Tesselaar
- Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | - Edward Wolin
- Montefiore Einstein Center for Cancer Care, Bronx, NY, USA
| | - Eric Van Cutsem
- University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
| | - Paola Tomassetti
- Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | | | - Maurizio Voi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | | | | | - Jiri Tomasek
- Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic
| | - Simron Singh
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Marianne Pavel
- Charité University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany
| | | | - Juan W Valle
- Institute of Cancer Sciences, The Christie NHS Foundation Trust, University of Manchester, Manchester, UK
| | - James C Yao
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
13
|
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017. [PMID: 28076709 DOI: 10.1056/nejmoa1607427/suppl_file/nejmoa1607427_disclosures.pdf] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
Abstract
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. RESULTS At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate group and 26 in the control group (P=0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the 177Lu-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. CONCLUSIONS Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).
Collapse
Affiliation(s)
- Jonathan Strosberg
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ghassan El-Haddad
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Edward Wolin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Andrew Hendifar
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - James Yao
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Beth Chasen
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Erik Mittra
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Pamela L Kunz
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Matthew H Kulke
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Heather Jacene
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - David Bushnell
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Thomas M O'Dorisio
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Richard P Baum
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Harshad R Kulkarni
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Martyn Caplin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Rachida Lebtahi
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Timothy Hobday
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ebrahim Delpassand
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Eric Van Cutsem
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Al Benson
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Rajaventhan Srirajaskanthan
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Marianne Pavel
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jaime Mora
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jordan Berlin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Enrique Grande
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Nicholas Reed
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ettore Seregni
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Kjell Öberg
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Maribel Lopera Sierra
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Paola Santoro
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Thomas Thevenet
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jack L Erion
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Philippe Ruszniewski
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Dik Kwekkeboom
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Eric Krenning
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| |
Collapse
|
14
|
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 376:125-135. [PMID: 28076709 PMCID: PMC5895095 DOI: 10.1056/nejmoa1607427] [Citation(s) in RCA: 1871] [Impact Index Per Article: 267.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. RESULTS At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate group and 26 in the control group (P=0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the 177Lu-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. CONCLUSIONS Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11 .).
Collapse
Affiliation(s)
- Jonathan Strosberg
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ghassan El-Haddad
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Edward Wolin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Andrew Hendifar
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - James Yao
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Beth Chasen
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Erik Mittra
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Pamela L Kunz
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Matthew H Kulke
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Heather Jacene
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - David Bushnell
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Thomas M O'Dorisio
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Richard P Baum
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Harshad R Kulkarni
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Martyn Caplin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Rachida Lebtahi
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Timothy Hobday
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ebrahim Delpassand
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Eric Van Cutsem
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Al Benson
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Rajaventhan Srirajaskanthan
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Marianne Pavel
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jaime Mora
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jordan Berlin
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Enrique Grande
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Nicholas Reed
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Ettore Seregni
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Kjell Öberg
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Maribel Lopera Sierra
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Paola Santoro
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Thomas Thevenet
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Jack L Erion
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Philippe Ruszniewski
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Dik Kwekkeboom
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| | - Eric Krenning
- From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.)
| |
Collapse
|
15
|
Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D, Hoersch D, Mirakhur B, Hoffmanns P, Houchard A, Caplin M, Baudin E. PUB119 Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.2090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Caplin M, Pavel M, Cwikła J, Phan A, Raderer M, Sedláčková E, Cadiot G, Wolin E, Capdevila J, Wall L, Rindi G, Liyanage N, Braun S, Ruszniewski P. Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Kwekkeboom D, Ruszniewski P, Krenning E. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.05] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Fisher G, Wolin E, Kunz P, Liyanage N, Mirakhur B, Lowenthal SP, Pommier R, Shaheen M, Vinik A. Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Buzzoni R, Fave G, Strosberg J, Voi M, Ridolfi A, Bubuteishvili-Pacaud L, Herbst F, Wolin E, Fazio N. Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw369.06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, Leyden J. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol 2016; 3:43-53. [PMID: 28717741 PMCID: PMC5493232 DOI: 10.1200/jgo.2015.002980] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Purpose Despite the considerable impact of neuroendocrine tumors (NETs) on patients’ daily lives, the journey of the patient with a NET has rarely been documented, with published data to date being limited to small qualitative studies. NETs are heterogeneous malignancies with nonspecific symptomology, leading to extensive health care use and diagnostic delays that affect survival. A large, international patient survey was conducted to increase understanding of the experience of the patient with a NET and identify unmet needs, with the aim of improving disease awareness and care worldwide. Methods An anonymous, self-reported survey was conducted (online or on paper) from February to May 2014, recruiting patients with NETs from > 12 countries as a collaboration between the International Neuroendocrine Cancer Alliance and Novartis Pharmaceuticals. Survey questions captured information on sociodemographics, clinical characteristics, NET diagnostic experience, disease impact/management, interaction with medical teams, NET knowledge/awareness, and sources of information. This article reports the most relevant findings on patient experience with NETs and the impact of NETs on health care system resources. Results A total of 1,928 patients with NETs participated. A NET diagnosis had a substantially negative impact on patients’ personal and work lives. Patients reported delayed diagnosis and extensive NET-related health care resource use. Patients desired improvement in many aspects of NET care, including availability of a wider range of NET-specific treatment options, better access to NET experts or specialist centers, and a more knowledgeable, better-coordinated/-aligned NET medical team. Conclusion This global patient-reported survey demonstrates the considerable burden of NETs with regard to symptoms, work and daily life, and health care resource use, and highlights considerable unmet needs. Further intervention is required to improve the patient experience among those with NETs.
Collapse
Affiliation(s)
- Simron Singh
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Dan Granberg
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Edward Wolin
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Richard Warner
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Maia Sissons
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Teodora Kolarova
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Grace Goldstein
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Marianne Pavel
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - Kjell Öberg
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| | - John Leyden
- , University of Toronto, Toronto, Ontario, Canada; and , Uppsala University Hospital, Uppsala, Sweden; , Montefiore Einstein Center for Cancer Care, Bronx, NY; , Mount Sinai School of Medicine, New York, NY; , NET Patient Foundation, Hockley Heath, United Kingdom; , APOZ & Friends, Sofia, Bulgaria; , The Carcinoid Cancer Foundation, Inc., White Plains, NY; , Charité Universitätsmedizin Berlin, Berlin, Germany; and , The Unicorn Foundation, Mosman, New South Wales, Australia
| |
Collapse
|
21
|
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Chaplin M, Baum R, Kunz P, Hobday T, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E, Hendifar A. O-009 NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw198.09] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Baum R, Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewsk P, Krenning E, Mittra E. SP-0570: Neuroendocrine tumours - personalised diagnosis and treatment using radiolabelled peptides. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31820-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968-977. [PMID: 26703889 PMCID: PMC6063317 DOI: 10.1016/s0140-6736(15)00817-x] [Citation(s) in RCA: 781] [Impact Index Per Article: 97.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population. METHODS In the randomised, double-blind, placebo-controlled, phase 3 RADIANT-4 trial, adult patients (aged ≥18 years) with advanced, progressive, well-differentiated, non-functional neuroendocrine tumours of lung or gastrointestinal origin were enrolled from 97 centres in 25 countries worldwide. Eligible patients were randomly assigned in a 2:1 ratio by an interactive voice response system to receive everolimus 10 mg per day orally or identical placebo, both with supportive care. Patients were stratified by tumour origin, performance status, and previous somatostatin analogue treatment. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival assessed by central radiology review, analysed by intention to treat. Overall survival was a key secondary endpoint. This trial is registered with ClinicalTrials.gov, number NCT01524783. FINDINGS Between April 3, 2012, and Aug 23, 2013, a total of 302 patients were enrolled, of whom 205 were allocated to everolimus 10 mg per day and 97 to placebo. Median progression-free survival was 11·0 months (95% CI 9·2-13·3) in the everolimus group and 3·9 months (3·6-7·4) in the placebo group. Everolimus was associated with a 52% reduction in the estimated risk of progression or death (hazard ratio [HR] 0·48 [95% CI 0·35-0·67], p<0·00001). Although not statistically significant, the results of the first pre-planned interim overall survival analysis indicated that everolimus might be associated with a reduction in the risk of death (HR 0·64 [95% CI 0·40-1·05], one-sided p=0·037, whereas the boundary for statistical significance was 0·0002). Grade 3 or 4 drug-related adverse events were infrequent and included stomatitis (in 18 [9%] of 202 patients in the everolimus group vs 0 of 98 in the placebo group), diarrhoea (15 [7%] vs 2 [2%]), infections (14 [7%] vs 0), anaemia (8 [4%] vs 1 [1%]), fatigue (7 [3%] vs 1 [1%]), and hyperglycaemia (7 [3%] vs 0). INTERPRETATION Treatment with everolimus was associated with significant improvement in progression-free survival in patients with progressive lung or gastrointestinal neuroendocrine tumours. The safety findings were consistent with the known side-effect profile of everolimus. Everolimus is the first targeted agent to show robust anti-tumour activity with acceptable tolerability across a broad range of neuroendocrine tumours, including those arising from the pancreas, lung, and gastrointestinal tract. FUNDING Novartis Pharmaceuticals Corporation.
Collapse
Affiliation(s)
- James C Yao
- University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Nicola Fazio
- Istituto Europeo di Oncologia, IRCCS, Milan, Italy
| | - Simron Singh
- Sunnybrook Health Sciences Centre, Toronto, ON, Canada
| | - Roberto Buzzoni
- Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
| | | | - Edward Wolin
- Markey Cancer Center, University of Kentucky, Lexington, KY, USA
| | - Jiri Tomasek
- Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | | | - Harald Lahner
- Universitaetsklinikum Essen, Zentrum f. Innere Medizin, Essen, Germany
| | - Maurizio Voi
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | | | | | | | - Juan W Valle
- Institute of Cancer Studies, University of Manchester, The Christie Hospital, Manchester, UK
| | | | - Eric Van Cutsem
- University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
| | - Margot Tesselaar
- Nederlands Kanker Instituut, Antoni van Leeuwenhoek, Amsterdam, Netherlands
| | | | - Do-Youn Oh
- Seoul National University Hospital, Seoul, South Korea
| | | | | | - Marianne E Pavel
- Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany
| |
Collapse
|
24
|
Zhu LM, Tang L, Qiao XW, Wolin E, Nissen NN, Dhall D, Chen J, Shen L, Chi Y, Yuan YZ, Ben QW, Lv B, Zhou YR, Bai CM, Chen J, Song YL, Song TT, Lu CM, Yu R, Chen YJ. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study. Medicine (Baltimore) 2016; 95:e2836. [PMID: 26886644 PMCID: PMC4998644 DOI: 10.1097/md.0000000000002836] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The presentation, pathology, and prognosis of pancreatic neuroendocrine tumors (PNETs) in Asian patients have not been studied in large cohorts. We hypothesized that the clinicopathological features of PNETs of Chinese patients might be different from those of US patients. The objectives of this study were to address whether PNETs in Chinese patients exhibit unique clinicopathological features and natural history, and can be graded and staged using the WHO/ENETS criteria. This is a retrospective review of medical records of patients with PNETs in multiple academic medical centers in China (7) and the United States (2). Tumor grading and staging were based on WHO/ENETS criteria. The clinicopathological features of PNETs of Chinese and US patients were compared. Univariate and multivariate analyses were performed to find associations between survival and patient demographics, tumor grade and stage, and other clinicopathological characteristics. A total of 977 (527 Chinese and 450 US) patients with PNETs were studied. In general, Chinese patients were younger than US patients (median age 46 vs 56 years). In Chinese patients, insulinomas were the most common (52.2%), followed by nonfunctional tumors (39.7%), whereas the order was reversed in US patients. Tumor grade distribution was similar in the 2 countries (G1: 57.5% vs 55.0%; G2: 38.5% vs 41.3%; and G3: 4.0% vs 3.7%). However, age, primary tumor size, primary tumor location, grade, and stage of subtypes of PNETs were significantly different between the 2 countries. The Chinese nonfunctional tumors were significantly larger than US ones (median size 4 vs 3 cm) and more frequently located in the head/neck region (54.9% vs 34.8%). The Chinese and US insulinomas were similar in size (median 1.5 cm) but the Chinese insulinomas relatively more frequently located in the head/neck region (48.3% vs 26.1%). Higher grade, advanced stage, metastasis, and larger primary tumor size were significantly associated with unfavorable survival in both countries. Several clinicopathological differences are found between Chinese and US PNETs but the PNETs of both countries follow a similar natural history. The WHO tumor grading and ENETS staging criteria are applicable to both Chinese and US patients.
Collapse
Affiliation(s)
- Li-Ming Zhu
- From the Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing (L-MZ, X-WQ, Y-LS, T-TS, C-ML, Y-JC); Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY (LT); Markey Cancer Center, University of Kentucky, Lexington, KY (EW); Department of Surgery (NNN); Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA (DD); Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou (JC); Department of Gastrointestinal Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute (LS); Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing (YC); Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai (Y-ZY, Q-WB); Department of Gastroenterology, the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou (BL); Department of Endocrinology, the Third Hospital of Hebei Medical University, Shijiazhuang (Y-RZ); Department of Oncology (C-MB); Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing (JC); and Division of Endocrinology and Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, University of California Los Angeles, Los Angeles, CA (RY)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Yao J, Singh S, Wolin E, Voi M, Pacaud L, Lincy J, Sachs C, Valle J, Van Cutsem E, Shimada Y, Oh DY. 134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv522.01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol 2015; 16:e435-e446. [PMID: 26370353 PMCID: PMC5023063 DOI: 10.1016/s1470-2045(15)00186-2] [Citation(s) in RCA: 142] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 03/24/2015] [Accepted: 03/26/2015] [Indexed: 02/06/2023]
Abstract
Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.
Collapse
Affiliation(s)
- Kjell Oberg
- Department of Medical Sciences, Endocrine Oncology, Uppsala University, Uppsala, Sweden
| | | | - Wouter De Herder
- Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands
| | | | - David Klimstra
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - David C Metz
- Division of Gastroenterology, University of Pennsylvania Health System, Philadelphia, PA, USA
| | - Anthony Heaney
- Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA
| | - Dik Kwekkeboom
- Department of Nuclear Medicine, Erasmus Medical Centre, Rotterdam, Netherlands
| | | | - Timothy Meyer
- University College London Cancer Institute, London, UK
| | - Steven F Moss
- Brown University, Liver Research Center, Providence, RI, USA
| | - Kay Washington
- Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Edward Wolin
- Markey Cancer Center, University of Kentucky, Lexington, KY, USA
| | - Eric Liu
- Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, USA
| | - James Goldenring
- Department of Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
27
|
Grenader T, Ruszniewski P, Pavel M, Cwikła J, Phan A, Raderer M, Sedláčková E, Cadiot G, Wolin E, Capdevila J, Wall L, Rindi G, Lang A, Gomez-Panzani E, Caplin M. 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31247-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Phan A, Caplin M, Pavel M, Cwikła J, Raderer M, Sedláčková E, Cadiot G, Wolin E, Capdevila J, Wall L, Rindi G, Langley A, Gomez-Panzani E, Ruszniewski P. 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31286-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Wolin E, Caplin M, Pavel M, Cwikła J, Phan A, Raderer M, Sedláčková E, Cadiot G, Capdevila J, Wall L, Rindi G, Langley A, Gomez-Panzani E, Ruszniewski P. 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31290-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
30
|
Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud L, Lincy J, Sachs C, Valle J, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh D, Strosberg J, Kulke M, Pavel M. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31928-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
31
|
Reich H, Czer L, Bannykh S, De Robertis M, Wolin E, Amersi F, Moriguchi J, Kobashigawa J, Arabia F. Total Artificial Heart Bridge to Transplantation for a Patient With Occult Intracardiac Malignancy: Case Report. Transplant Proc 2015; 47:2291-4. [DOI: 10.1016/j.transproceed.2015.04.083] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2015] [Accepted: 04/28/2015] [Indexed: 10/23/2022]
|
32
|
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Mittra E, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Ruszniewski P, Kwekkeboom D. 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31929-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
33
|
Pavel M, Caplin M, Ćwikła JB, Phan A, Raderer M, Sedláčková E, Cadiot G, Wolin E, Capdevila J, Wall L, Rindi G, Langley A, Gomez-Panzani E, Ruszniewski P. Antitumor activity of lanreotide autogel (LAN) in enteropancreatic net patients: The CLARINET open-label extension (OLE) study. Exp Clin Endocrinol Diabetes 2015. [DOI: 10.1055/s-0035-1547777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Steen S, Wolin E, Geller SA, Colquhoun S. Primary hepatocellular carcinoma ("hepatoid" carcinoma) of the pancreas: a case report and review of the literature. Clin Case Rep 2013; 1:66-71. [PMID: 25356215 PMCID: PMC4184752 DOI: 10.1002/ccr3.26] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2013] [Revised: 09/19/2013] [Accepted: 10/10/2013] [Indexed: 12/13/2022] Open
Abstract
Key Clinical Message We present a case of hepatocellular carcinoma located within the pancreas. These tumors occur in the body and tail of the pancreas, with a male predominance, and at a younger age. Tumors with pure hepatocellular histopathology have better survival and recurrence rates and should be offered surgical therapy if possible.
Collapse
Affiliation(s)
- Shawn Steen
- Department of Surgical Oncology, John Wayne Cancer Institute Santa Monica, California
| | - Edward Wolin
- Department of Medical Oncology, Cedars Sinai Medical Center Beverly Hills, California
| | - Stephen A Geller
- Department of Pathology, Cedars Sinai Medical Center Beverly Hills, California
| | - Steven Colquhoun
- Department of Surgery, Cedars Sinai Medical Center Beverly Hills, California
| |
Collapse
|
35
|
Hari DM, Goff SL, Reich HJ, Leung AM, Sim MS, Lee JH, Wolin E, Amersi F. Small bowel carcinoid: Location isn’t everything! World J Gastrointest Surg 2013; 5:239-244. [PMID: 23983905 PMCID: PMC3753437 DOI: 10.4240/wjgs.v5.i8.239] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 06/18/2013] [Accepted: 08/13/2013] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the prognostic significance of the primary site of disease for small bowel carcinoid (SBC) using a population-based analysis.
METHODS: The Surveillance, Epidemiology and End Results (SEER) database was queried for histologically confirmed SBC between the years 1988 and 2009. Overall survival (OS) and disease-specific survival (DSS) were analyzed using the Kaplan-Meier method and compared using Log rank testing. Log rank and multivariate Cox regression analyses were used to identify predictors of survival using age, year of diagnosis, race, gender, tumor histology/size/location, tumor-node-metastasis stage, number of lymph nodes (LNs) examined and percent of LNs with metastases.
RESULTS: Of the 3763 patients, 51.2% were male with a mean age of 62.13 years. Median follow-up was 50 mo. The 10-year OS and DSS for duodenal primaries were significantly better when compared to jejunal and ileal primaries (P = 0.02 and < 0.0001, respectively). On multivariate Cox regression analysis, after adjusting for multiple factors, primary site location was not a significant predictor of survival (P = 0.752 for OS and P = 0.966 DSS) while age, number of primaries, number of LNs examined, T-stage and M-stage were independent predictors of survival.
CONCLUSION: This 21-year, population-based study of SBC challenges the concept that location of the primary lesion alone is a significant predictor of survival.
Collapse
|
36
|
Abstract
We report a 50-year-old woman whose atypical lung carcinoid presented as a single subcutaneous nodule. Biopsy of the nodule revealed neuroendocrine carcinoma likely from the lungs. Imaging studies revealed masses in lungs, pelvis and right axilla, and a seizure a few months later lead to discovery of brain metastasis. This case illustrates that an apparently innocuous subcutaneous nodule could be the initial presentation of an otherwise asymptomatic but widely metastatic atypical lung carcinoid. Physicians should be aware of signs of skin metastasis from lung malignancies and judiciously select patients with subcutaneous nodule for biopsy.
Collapse
Affiliation(s)
- Run Yu
- Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Edward Wolin
- Carcinoid and Neuroendocrine Tumor Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Xuemo Fan
- Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
37
|
Nalawadi SS, Siegel RJ, Wolin E, Yu R, Trento A, Shiota T, Tolstrup K, Luthringer D, Gurudevan S. Morphologic Features of Carcinoid Heart Disease as Assessed by Three-Dimensional Transesophageal Echocardiography. Echocardiography 2010; 27:1098-105. [DOI: 10.1111/j.1540-8175.2010.01207.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
38
|
Lachniet J, Afanasev A, Arenhövel H, Brooks WK, Gilfoyle GP, Higinbotham D, Jeschonnek S, Quinn B, Vineyard MF, Adams G, Adhikari KP, Amaryan MJ, Anghinolfi M, Asavapibhop B, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Batourine V, Battaglieri M, Beard K, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Bonner BE, Bookwalter C, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Bültmann S, Burkert VD, Calarco JR, Careccia SL, Carman DS, Casey L, Cheng L, Cole PL, Coleman A, Collins P, Cords D, Corvisiero P, Crabb D, Crede V, Cummings JP, Dale D, Daniel A, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dhamija S, Dharmawardane KV, Dhuga KS, Dickson R, Djalali C, Dodge GE, Doughty D, Dragovitsch P, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Empl A, Eugenio P, Fatemi R, Fedotov G, Fersch R, Feuerbach RJ, Forest TA, Fradi A, Gabrielyan MY, Garçon M, Gavalian G, Gevorgyan N, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Golovatch E, Gothe RW, Graham L, Griffioen KA, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hanretty C, Hardie J, Hassall N, Heddle D, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hu J, Huertas M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kageya T, Kalantarians N, Keller D, Kellie JD, Khandaker M, Khetarpal P, Kim KY, Kim K, Kim W, Klein A, Klein FJ, Klusman M, Konczykowski P, Kossov M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Kuznetsov V, Laget JM, Langheinrich J, Lawrence D, Lima ACS, Livingston K, Lowry M, Lu HY, Lukashin K, Maccormick M, Malace S, Manak JJ, Markov N, Mattione P, McAleer S, McCracken ME, McKinnon B, McNabb JWC, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Mineeva T, Minehart R, Mirazita M, Miskimen R, Mokeev V, Moreno B, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, O'Rielly GV, Osipenko M, Ostrovidov AI, Park K, Park S, Pasyuk E, Paterson C, Pereira SA, Philips SA, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Polli E, Popa I, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Qin LM, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Rosner G, Rossi P, Rowntree D, Rubin PD, Sabatié F, Saini MS, Salamanca J, Salgado C, Sandorfi A, Santoro JP, Sapunenko V, Schott D, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shaw J, Shvedunov NV, Skabelin AV, Smith ES, Smith LC, Sober DI, Sokhan D, Starostin A, Stavinsky A, Stepanyan S, Stepanyan SS, Stokes BE, Stoler P, Stopani KA, Strakovsky II, Strauch S, Suleiman R, Taiuti M, Taylor S, Tedeschi DJ, Thompson R, Tkabladze A, Tkachenko S, Ungaro M, Vlassov AV, Watts DP, Wei X, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Yun J, Yurov M, Zana L, Zhang J, Zhao B, Zhao ZW. Precise measurement of the neutron magnetic form factor G(M)n in the few-GeV2 region. Phys Rev Lett 2009; 102:192001. [PMID: 19518944 DOI: 10.1103/physrevlett.102.192001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/10/2008] [Indexed: 05/27/2023]
Abstract
The neutron elastic magnetic form factor was extracted from quasielastic electron scattering on deuterium over the range Q;{2}=1.0-4.8 GeV2 with the CLAS detector at Jefferson Lab. High precision was achieved with a ratio technique and a simultaneous in situ calibration of the neutron detection efficiency. Neutrons were detected with electromagnetic calorimeters and time-of-flight scintillators at two beam energies. The dipole parametrization gives a good description of the data.
Collapse
Affiliation(s)
- J Lachniet
- Carnegie Mellon University, Pittsburgh, Pennsylvania 15213, USA and Old Dominion University, Norfolk, Virginia 23529, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Nozar M, Salgado C, Weygand DP, Guo L, Adams G, Li J, Eugenio P, Amaryan MJ, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bonner BE, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Carnahan B, Casey L, Cazes A, Chen S, Cheng L, Cole PL, Collins P, Coltharp P, Cords D, Corvisiero P, Crabb D, Crannell H, Crede V, Cummings JP, Dale D, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dhuga KS, Dickson R, Djalali C, Dodge GE, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Fatemi R, Fedotov G, Feuerbach RJ, Forest TA, Fradi A, Funsten H, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gothe RW, Griffioen KA, Guidal M, Guillo M, Guler N, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hanretty C, Hardie J, Hassall N, Heddle D, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Kuznetsov V, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Livingston K, Lu HY, Maccormick M, Markov N, Mattione P, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Mirazita M, Miskimen R, Mokeev V, Moreno B, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, O'Rielly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Philips SA, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Polli E, Popa I, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Qin LM, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Rubin PD, Sabatié F, Salamanca J, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Skabelin AV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Thoma U, Tkabladze A, Tkachenko S, Todor L, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao ZW. Search for the photoexcitation of exotic mesons in the pi+pi+pi- system. Phys Rev Lett 2009; 102:102002. [PMID: 19392105 DOI: 10.1103/physrevlett.102.102002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2008] [Indexed: 05/27/2023]
Abstract
A search for exotic mesons in the pi;{+}pi;{+}pi;{-} system photoproduced by the charge exchange reaction gammap-->pi;{+}pi;{+}pi;{-}(n) was carried out by the CLAS Collaboration at Jefferson Lab. A tagged-photon beam with energies in the 4.8 to 5.4 GeV range, produced through bremsstrahlung from a 5.744 GeV electron beam, was incident on a liquid-hydrogen target. A partial wave analysis was performed on a sample of 83 000 events, the highest such statistics to date in this reaction at these energies. The main objective of this study was to look for the photoproduction of an exotic J;{PC}=1;{-+} resonant state in the 1 to 2 GeV mass range. Our partial wave analysis shows production of the a_{2}(1320) and the pi_{2}(1670) mesons, but no evidence for the a_{1}(1260), nor the pi_{1}(1600) exotic state at the expected levels. An upper limit of 13.5 nb is determined for the exotic pi_{1}(1600) cross section, less than 2% of the a_{2}(1320) production.
Collapse
Affiliation(s)
- M Nozar
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Battaglieri M, De Vita R, Szczepaniak AP, Adhikari KP, Aghasyan M, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Bedlinskiy I, Bellis M, Benmouna N, Berman BL, Bibrzycki L, Biselli AS, Bookwalter C, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Calarco JR, Careccia SL, Carman DS, Casey L, Chen S, Cheng L, Clinton E, Cole PL, Collins P, Crabb D, Crannell H, Crede V, Cummings JP, Dale D, Daniel A, Dashyan N, De Masi R, De Sanctis E, Degtyarenko PV, Deur A, Dhamija S, Dharmawardane KV, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Fersch R, Forest TA, Fradi A, Gabrielyan MY, Gan L, Garçon M, Gasparian A, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Glamazdin O, Goett J, Goetz JT, Gohn W, Golovatch E, Gordon CIO, Gothe RW, Graham L, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hanretty C, Hardie J, Hassall N, Heddle D, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kageya T, Kalantarians N, Keller D, Kellie JD, Khandaker M, Khetarpal P, Kim W, Klein A, Klein FJ, Klimenko AV, Konczykowski P, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Kuznetsov V, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Lesniak L, Li J, Livingston K, Lowry M, Lu HY, Maccormick M, Malace S, Markov N, Mattione P, McCracken ME, McKinnon B, Mecking BA, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Mineeva T, Minehart R, Mirazita M, Miskimen R, Mochalov V, Mokeev V, Moreno B, Moriya K, Morrow SA, Moteabbed M, Munevar E, Mutchler GS, Nadel-Turonski P, Nakagawa I, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Park S, Pasyuk E, Paris M, Paterson C, Pereira SA, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Rosner G, Rossi P, Sabatié F, Saini MS, Salamanca J, Salgado C, Sandorfi A, Santoro JP, Sapunenko V, Schott D, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith ES, Smith LC, Sober DI, Sokhan D, Starostin A, Stavinsky A, Stepanyan S, Stepanyan SS, Stokes BE, Stoler P, Stopani KA, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Teymurazyan A, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Wei X, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Yurov M, Zana L, Zhang J, Zhao B, Zhao ZW. Measurement of direct f0(980) photoproduction on the proton. Phys Rev Lett 2009; 102:102001. [PMID: 19392104 DOI: 10.1103/physrevlett.102.102001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2008] [Indexed: 05/27/2023]
Abstract
We report on the results of the first measurement of exclusive f_{0}(980) meson photoproduction on protons for E_{gamma}=3.0-3.8 GeV and -t=0.4-1.0 GeV2. Data were collected with the CLAS detector at the Thomas Jefferson National Accelerator Facility. The resonance was detected via its decay in the pi;{+}pi;{-} channel by performing a partial wave analysis of the reaction gammap-->ppi;{+}pi;{-}. Clear evidence of the f_{0}(980) meson was found in the interference between P and S waves at M_{pi;{+}pi;{-}} approximately 1 GeV. The S-wave differential cross section integrated in the mass range of the f_{0}(980) was found to be a factor of about 50 smaller than the cross section for the rho meson. This is the first time the f_{0}(980) meson has been measured in a photoproduction experiment.
Collapse
Affiliation(s)
- M Battaglieri
- Istituto Nazionale di Fisica Nucleare, Sezione di Genova, 16146 Genova, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Girod FX, Niyazov RA, Avakian H, Ball J, Bedlinskiy I, Burkert VD, De Masi R, Elouadrhiri L, Garçon M, Guidal M, Jo HS, Joo K, Kubarovsky V, Kuleshov SV, MacCormick M, Niccolai S, Pogorelko O, Sabatié F, Stepanyan S, Stoler P, Ungaro M, Zhao B, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Asryan G, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Battaglieri M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Casey L, Chen S, Cheng L, Cole PL, Collins P, Coltharp P, Crabb D, Crede V, Dashyan N, De Sanctis E, De Vita R, Degtyarenko PV, Deur A, Dharmawardane KV, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Eugenio P, Fedotov G, Feldman G, Funsten H, Gavalian G, Gilfoyle GP, Giovanetti KL, Goetz JT, Gonenc A, Gothe RW, Griffioen KA, Guler N, Guo L, Gyurjyan V, Hafidi K, Hakobyan H, Hanretty C, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Johnstone JR, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kuhn J, Kuhn SE, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Livingston K, Lu HY, Markov N, Mattione P, Mazouz M, McKinnon B, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Michel B, Mikhailov K, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pozdniakov S, Price JW, Procureur S, Prok Y, Protopopescu D, Raue BA, Ricco G, Ripani M, Ritchie BG, Rosner G, Rossi P, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stokes BE, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Tur C, Vineyard MF, Vlassov AV, Voutier E, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao ZW. Measurement of deeply virtual compton scattering beam-spin asymmetries. Phys Rev Lett 2008; 100:162002. [PMID: 18518188 DOI: 10.1103/physrevlett.100.162002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2007] [Indexed: 05/26/2023]
Abstract
The beam-spin asymmetries in the hard exclusive electroproduction of photons on the proton (e p-->epgamma) were measured over a wide kinematic range and with high statistical accuracy. These asymmetries result from the interference of the Bethe-Heitler process and of deeply virtual Compton scattering. Over the whole kinematic range (x(B) from 0.11 to 0.58, Q2 from 1 to 4.8 GeV2, -t from 0.09 to 1.8 GeV2), the azimuthal dependence of the asymmetries is compatible with expectations from leading-twist dominance, A approximately a sinphi/(1+c cosphi). This extensive set of data can thus be used to constrain significantly the generalized parton distributions of the nucleon in the valence quark sector.
Collapse
Affiliation(s)
- F X Girod
- CEA-Saclay, Service de Physique Nucléaire, 91191 Gif-sur-Yvette, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ireland DG, McKinnon B, Protopopescu D, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Battaglieri M, Bedlinskiy I, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Casey L, Chen S, Cheng L, Cole PL, Collins P, Coltharp P, Crabb D, Crede V, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Deur A, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Fradi A, Funsten H, Garçon M, Gavalian G, Gevorgyan N, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gonenc A, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hafidi K, Hakobyan H, Hanretty C, Hassall N, Hersman FW, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ishkhanov BS, Isupov EL, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuleshov SV, Kuznetsov V, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Livingston K, Lu HY, Maccormick M, Markov N, Mattione P, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Mirazita M, Miskimen R, Mokeev V, Moreno B, Moriya K, Morrow SA, Moteabbed M, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Pereira SA, Pierce J, Pivnyuk N, Pogorelko O, Pozdniakov S, Price JW, Procureur S, Prok Y, Raue BA, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao ZW. Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett 2008; 100:052001. [PMID: 18352361 DOI: 10.1103/physrevlett.100.052001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2007] [Indexed: 05/26/2023]
Abstract
We examine the results of two measurements by the CLAS collaboration, one of which claimed evidence for a Theta(+) pentaquark, while the other found no such evidence. The unique feature of these two experiments was that they were performed with the same experimental setup. Using a Bayesian analysis, we find that the results of the two experiments are in fact compatible with each other, but that the first measurement did not contain sufficient information to determine unambiguously the existence of a Theta(+). Further, we suggest a means by which the existence of a new candidate particle can be tested in a rigorous manner.
Collapse
Affiliation(s)
- D G Ireland
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nasseripour R, Wood MH, Djalali C, Weygand DP, Tur C, Mosel U, Muehlich P, Adams G, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Carnahan B, Casey L, Chen S, Cole PL, Collins P, Coltharp P, Crabb D, Crannell H, Crede V, Cummings JP, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dickson R, Dodge GE, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Feuerbach RJ, Funsten H, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gordon CIO, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hanretty C, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Johnstone JR, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Li J, Livingston K, Lu HY, Maccormick M, Markov N, Mattione P, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Sharov D, Shvedunov NV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Tkabladze A, Tkachenko S, Todor L, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Williams M, Wolin E, Yegneswaran A, Zana L, Zhang B, Zhang J, Zhao B, Zhao ZW. Search for medium modifications of the rho meson. Phys Rev Lett 2007; 99:262302. [PMID: 18233570 DOI: 10.1103/physrevlett.99.262302] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2007] [Indexed: 05/25/2023]
Abstract
The photoproduction of vector mesons on various nuclei has been studied using the CLAS detector at Jefferson Laboratory. The vector mesons, rho, omega, and varphi, are observed via their decay to e;{+}e;{-}, in order to reduce the effects of final-state interactions in the nucleus. Of particular interest are possible in-medium effects on the properties of the rho meson. The rho mass spectrum is extracted from the data on various nuclei, 2H, C, Fe, and Ti. We observe no significant mass shift and some broadening consistent with expected collisional broadening for the rho meson.
Collapse
Affiliation(s)
- R Nasseripour
- University of South Carolina, Columbia, South Carolina 29208, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Egiyan KS, Asryan G, Gevorgyan N, Griffioen KA, Laget JM, Kuhn SE, Adams G, Amaryan MJ, Ambrozewicz P, Anghinolfi M, Audit G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Batourine V, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Blaszczyk L, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Cazes A, Chen S, Cole PL, Collins P, Coltharp P, Cords D, Corvisiero P, Crabb D, Crede V, Cummings JP, Dashyan N, De Masi R, De Vita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dickson R, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, El Fassi L, Elouadrhiri L, Eugenio P, Fatemi R, Fedotov G, Feldman G, Feuerbach RJ, Fersch R, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gonenc A, Gordon CIO, Gothe RW, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hanretty C, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kalantarians N, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Krahn Z, Kramer LH, Kubarovsky V, Kuhn J, Kuleshov SV, Lachniet J, Langheinrich J, Lawrence D, Li J, Livingston K, Lu HY, Maccormick M, Marchand C, Markov N, Mattione P, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Moriya K, Morrow SA, Moteabbed M, Mueller J, Munevar E, Mutchler GS, Nadel-Turonski P, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, O'Rielly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Anefalos Pereira S, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salamanca J, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shvedunov NV, Skabelin AV, Smith ES, Smith LC, Sober DI, Sokhan D, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strauch S, Taiuti M, Tedeschi DJ, Thoma U, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao ZW. Experimental study of exclusive 2H(e,e'p)n reaction mechanisms at high Q2. Phys Rev Lett 2007; 98:262502. [PMID: 17678084 DOI: 10.1103/physrevlett.98.262502] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2007] [Indexed: 05/16/2023]
Abstract
The reaction 2H(e,e'p)n has been studied with full kinematic coverage for photon virtuality 1.75<Q2<5.5 GeV2. Comparisons of experimental data with theory indicate that for very low values of neutron recoil momentum (p(n)<100 MeV/c) the neutron is primarily a spectator and the reaction can be described by the plane-wave impulse approximation. For 100<p(n)<750 MeV/c, proton-neutron rescattering dominates the cross section, while Delta production followed by the NDelta-->NN transition is the primary contribution at higher momenta.
Collapse
Affiliation(s)
- K S Egiyan
- Yerevan Physics Institute, 375036 Yerevan, Armenia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Ungaro M, Stoler P, Aznauryan I, Burkert VD, Joo K, Smith LC, Adams G, Amarian M, Ambrozewicz P, Anghinolfi M, Asryan G, Audit G, Avakian H, Bagdasaryan H, Ball JP, Baltzell NA, Barrow S, Batourine V, Battaglieri M, Bedliski I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Bonner BE, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Cazes A, Chen S, Cole PL, Coltharp P, Cords D, Corvisiero P, Crabb D, Cummings JP, Sanctis ED, Devita R, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, Elouadrhiri L, Eugenio P, Fatemi R, Fedotov G, Feldman G, Feuerbach RJ, Funsten H, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz J, Gordon CIO, Gothe RW, Griffioen KA, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hakobyan RS, Hardie J, Heddle D, Hersman FW, Hleiqawi I, Holtrop M, Hicks K, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Ito MM, Jenkins D, Jo HS, Juengst HG, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Li J, Livingston K, Marchand C, Markov N, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mehrabyan S, Melone JJ, Mestayer MD, Meyer CA, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Morand L, Morrow SA, Mueller J, Mutchler GS, Napolitano J, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula M, Niyazov RA, Nozar M, O'rielly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Philips SA, Pivnyuk N, Pocanic D, Pogorelko O, Polli E, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Qin LM, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Rubin PD, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Skabelin AV, Smith ES, Sober DI, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Thoma U, Tkabladze A, Todor L, Tkachenko S, Tur C, Vineyard MF, Vlassov AV, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang B, Zhang J, Zhao B. Measurement of the N-->Delta(+)(1232) transition at high-momentum transfer by pi(0) electroproduction. Phys Rev Lett 2006; 97:112003. [PMID: 17025879 DOI: 10.1103/physrevlett.97.112003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2006] [Indexed: 05/12/2023]
Abstract
We report a new measurement of the exclusive electroproduction reaction gamma(*)p-->pi(0)p to explore the evolution from soft nonperturbative physics to hard processes via the Q(2) dependence of the magnetic (M(1+)), electric (E(1+)), and scalar (S(1+)) multipoles in the N-->Delta transition. 9000 differential cross section data points cover W from threshold to 1.4 GeV/c(2), 4pi center-of-mass solid angle, and Q(2) from 3 to 6 GeV(2)/c(2), the highest yet achieved. It is found that the magnetic form factor G(M)(*) decreases with Q(2) more steeply than the proton magnetic form factor, the ratio E(1+)/M(1+) is small and negative, indicating strong helicity nonconservation, and the ratio S(1+)/M(1+) is negative, while its magnitude increases with Q(2).
Collapse
Affiliation(s)
- M Ungaro
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kubarovsky V, Battaglieri M, De Vita R, Goett J, Guo L, Mutchler GS, Stoler P, Weygand DP, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Bedlinskiy I, Bellis M, Benmouna N, Berman BL, Biselli AS, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Chen S, Clinton E, Cole PL, Collins P, Coltharp P, Crabb D, Crannell H, Crede V, Cummings JP, De Masi R, Dale D, De Sanctis E, Degtyarenko PV, Deur A, Dharmawardane KV, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, Elouadrhiri L, Eugenio P, Fedotov G, Funsten H, Gabrielyan MY, Gan L, Garçon M, Gasparian A, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Glamazdin O, Goetz JT, Golovach E, Gonenc A, Gordon CIO, Gothe RW, Griffioen KA, Guidal M, Guler N, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan RS, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Kramer LH, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Li J, Livingston K, Lu H, MacCormick M, Markov N, McKinnon B, Mecking BA, Melone JJ, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mochalov V, Mokeev V, Morand L, Morrow SA, Moteabbed M, Nadel-Turonski P, Nakagawa I, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shvedunov NV, Smith ES, Smith LC, Sober DI, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Strakovsky II, Strauch S, Taiuti M, Tedeschi DJ, Teymurazyan A, Thoma U, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Weinstein LB, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B. Search for Theta++ pentaquarks in the exclusive reaction gammap-->K+K-p. Phys Rev Lett 2006; 97:102001. [PMID: 17025804 DOI: 10.1103/physrevlett.97.102001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2006] [Indexed: 05/12/2023]
Abstract
The reaction gammap --> pK+K- was studied at Jefferson Lab with photon energies from 1.8 to 3.8 GeV using a tagged photon beam. The goal was to search for a Theta++ pentaquark, a narrow, doubly charged baryon state having strangeness S=+1 and isospin I=1, in the pK+ invariant mass spectrum. No statistically significant evidence of a Theta++ was found. Upper limits on the total and differential cross section for the reaction gammap --> K-Theta++ were obtained in the mass range from 1.5 to 2.0 GeV/c2, with an upper limit for a narrow resonance with a mass M(Theta++) = 1.54 GeV/c2 of about 0.15 nb, 95% C.L.. This result places a stringent upper limit on the Theta++ width Gamma(Theta++) <0.1 MeV/c2.
Collapse
Affiliation(s)
- V Kubarovsky
- Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Chen S, Avakian H, Burkert VD, Eugenio P, Adams G, Amarian M, Ambrozewicz P, Anghinolfi M, Asryan G, Bagdasaryan H, Baillie N, Ball JP, Baltzell NA, Barrow S, Batourine V, Battaglieri M, Beard K, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Bonner BE, Bouchigny S, Boiarinov S, Bosted P, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Butuceanu C, Calarco JR, Careccia SL, Carman DS, Carnahan B, Cazes A, Cole PL, Collins P, Coltharp P, Cords D, Corvisiero P, Crabb D, Crannell H, Crede V, Cummings JP, DeMasi R, DeVita R, De Sanctis E, Degtyarenko PV, Denizli H, Dennis L, Deur A, Dharmawardane KV, Dhuga KS, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Fatemi R, Fedotov G, Feldman G, Feuerbach RJ, Forest TA, Funsten H, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Golovatch E, Gonenc A, Gothe RW, Griffioen KA, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hardie J, Heddle D, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Huertas M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Keith C, Kellie JD, Khandaker M, Kim KY, Kim K, Kim W, Klein A, Klein FJ, Klusman M, Kossov M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Li J, Lima ACS, Livingston K, Lu H, Lukashin K, MacCormick M, Markov N, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Morand L, Morrow SA, Moteabbed M, Mueller J, Mutchler GS, Nadel-Turonski P, Napolitano J, Nasseripour R, Natasha N, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, O'Rielly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Philips SA, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Polli E, Popa I, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Qin LM, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Rowntree D, Rubin PD, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shaw J, Shvedunov NV, Skabelin AV, Smith ES, Smith LC, Sober DI, Stavinsky A, Stepanyan SS, Stepanyan S, Stokes BE, Stoler P, Strakovsky II, Strauch S, Suleiman R, Taiuti M, Tedeschi DJ, Thoma U, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vanderhaeghen M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Yun J, Zana L, Zhang J, Zhao B, Zhao Z. Measurement of deeply virtual compton scattering with a polarized-proton target. Phys Rev Lett 2006; 97:072002. [PMID: 17026221 DOI: 10.1103/physrevlett.97.072002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2006] [Indexed: 05/12/2023]
Abstract
The longitudinal target-spin asymmetry AUL for the exclusive electroproduction of high-energy photons was measured for the first time in ep-->e;'pgamma. The data have been accumulated at JLab with the CLAS spectrometer using 5.7 GeV electrons and a longitudinally polarized NH3 target. A significant azimuthal angular dependence was observed, resulting from the interference of the deeply virtual Compton scattering and Bethe-Heitler processes. The amplitude of the sinvarphi moment is 0.252+/-0.042stat+/-0.020sys. Theoretical calculations are in good agreement with the magnitude and the kinematic dependence of the target-spin asymmetry, which is sensitive to the generalized parton distributions H and H.
Collapse
Affiliation(s)
- S Chen
- Florida State University, Tallahassee, Florida 32306, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Niccolai S, Mirazita M, Rossi P, Baltzell NA, Carman DS, Hicks K, McKinnon B, Mibe T, Stepanyan S, Tedeschi DJ, Adams G, Ambrozewicz P, Anefalos Pereira S, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Batourine V, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Berman BL, Biselli AS, Boiarinov S, Bouchigny S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Carnahan B, Chen S, Cole PL, Collins P, Coltharp P, Crabb D, Crannell H, Crede V, Cummings JP, Dashyan N, Degtyarenko PV, De Masi R, Deppman A, De Sanctis E, Deur A, Devita R, Dharmawardane KV, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Funsten H, Garçon M, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gonenc A, Gordon CIO, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hafidi K, Hakobyan H, Hakobyan RS, Hardie J, Hersman FW, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Klimenko AV, Kossov M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Langheinrich J, Lawrence D, Lee T, Li J, Livingston K, Lu H, MacCormick M, Markov N, Mecking BA, Mellor J, Melone JJ, Mestayer MD, Meyer CA, Mikhailov K, Minehart R, Miskimen R, Mokeev V, Morand L, Morrow SA, Moteabbed M, Mutchler GS, Nadel-Turonski P, Napolitano J, Nasseripour R, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, de Oliveira Echeimberg J, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shvedunov NV, Smith ES, Smith LC, Sober DI, Stavinsky A, Stepanyan SS, Stokes BE, Stoler P, Strakovsky II, Strauch S, Taiuti M, Thoma U, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Watts DP, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao Z. Search for the Theta+ Pentaquark in the gammad--> DeltanK+ reaction measured with the CLAS spectrometer. Phys Rev Lett 2006; 97:032001. [PMID: 16907494 DOI: 10.1103/physrevlett.97.032001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2006] [Indexed: 05/11/2023]
Abstract
For the first time, the reaction gammad-->DeltanK+ has been analyzed in order to search for the exotic pentaquark baryon Theta+(1540). The data were taken at Jefferson Laboratory, using the Hall-B tagged-photon beam of energy between 0.8 and 3.6 GeV and the CEBAF Large Acceptance Spectrometer (CLAS). No statistically significant structures were observed in the nK+ invariant-mass distribution. The upper limit on the gammad-->DeltaTheta+ integrated cross section has been calculated and found to be between 5 and 25 nb, depending on the production model assumed. The upper limit on the differential cross section is also reported.
Collapse
Affiliation(s)
- S Niccolai
- Institut de Physique Nucléaire, Orsay, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
McKinnon B, Hicks K, Baltzell NA, Carman DS, Mestayer MD, Mibe T, Mirazita M, Niccolai S, Rossi P, Stepanyan S, Tedeschi DJ, Ambrozewicz P, Anghinolfi M, Asryan G, Avakian H, Bagdasaryan H, Baillie N, Ball JP, Batourine V, Battaglieri M, Bedlinskiy I, Bellis M, Benmouna N, Berman BL, Biselli AS, Bouchigny S, Boiarinov S, Bradford R, Branford D, Briscoe WJ, Brooks WK, Bültmann S, Burkert VD, Butuceanu C, Calarco JR, Careccia SL, Chen S, Cole PL, Collins P, Coltharp P, Crabb D, Crede V, Dale D, De Masi R, DeVita R, De Sanctis E, Degtyarenko PV, Deur A, Djalali C, Dodge GE, Donnelly J, Doughty D, Dugger M, Dzyubak OP, Egiyan H, Egiyan KS, Elouadrhiri L, Eugenio P, Fedotov G, Feldman G, Funsten H, Gabrielyan M, Gan L, Garçon M, Gasparian A, Gavalian G, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Gonenc A, Gothe RW, Griffioen KA, Guidal M, Guler N, Guo L, Gyurjyan V, Hakobyan RS, Hersman FW, Hleiqawi I, Holtrop M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kellie JD, Khandaker M, Kim W, Klein A, Klein FJ, Kossov M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov SV, Lachniet J, Langheinrich J, Lawrence D, Livingston K, Lu H, MacCormick M, Mecking BA, Meyer CA, Mikhailov K, Miskimen R, Mokeev V, Morrow SA, Moteabbed M, Mutchler GS, Nakagawa I, Nadel-Turonski P, Nasseripour R, Niculescu G, Niculescu I, Niczyporuk BB, Niroula MR, Niyazov RA, Nozar M, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Paterson C, Pierce J, Pivnyuk N, Pogorelko O, Pozdniakov S, Price JW, Prok Y, Protopopescu D, Raue BA, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Smith ES, Smith LC, Sober DI, Stavinsky A, Stepanyan SS, Stokes BE, Stoler P, Strakovsky II, Strauch S, Taiuti M, Teymurazyan A, Thoma U, Tkabladze A, Tkachenko S, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Weinstein LB, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Zana L, Zhang J, Zhao B, Zhao Z. Search for the Theta+ pentaquark in the reaction gammad --> pK-K+n. Phys Rev Lett 2006; 96:212001. [PMID: 16803230 DOI: 10.1103/physrevlett.96.212001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/14/2006] [Indexed: 05/10/2023]
Abstract
A search for the Theta+ in the reaction gammad --> pK-K+n was completed using the CLAS detector at Jefferson Lab. A study of the same reaction, published earlier, reported the observation of a narrow Theta+ resonance. The present experiment, with more than 30 times the integrated luminosity of our earlier measurement, does not show any evidence for a narrow pentaquark resonance. The angle-integrated upper limit on Theta+ production in the mass range of 1.52-1.56 GeV/c2 for the gammad --> pK-Theta+ reaction is 0.3 nb (95% C.L.). This upper limit depends on assumptions made for the mass and angular distribution of Theta+ production. Using Lambda(1520) production as an empirical measure of rescattering in the deuteron, the cross section upper limit for the elementary gamman --> K-Theta+ reaction is estimated to be a factor of 10 higher, i.e., approximately 3 nb (95% C.L.).
Collapse
Affiliation(s)
- B McKinnon
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Egiyan KS, Dashyan NB, Sargsian MM, Strikman MI, Weinstein LB, Adams G, Ambrozewicz P, Anghinolfi M, Asavapibhop B, Asryan G, Avakian H, Baghdasaryan H, Baillie N, Ball JP, Baltzell NA, Batourine V, Battaglieri M, Bedlinskiy I, Bektasoglu M, Bellis M, Benmouna N, Biselli AS, Bonner BE, Bouchigny S, Boiarinov S, Bradford R, Branford D, Brooks WK, Bültmann S, Burkert VD, Bultuceanu C, Calarco JR, Careccia SL, Carman DS, Carnahan B, Chen S, Cole PL, Coltharp P, Corvisiero P, Crabb D, Crannell H, Cummings JP, De Sanctis E, DeVita R, Degtyarenko PV, Denizli H, Dennis L, Dharmawardane KV, Djalali C, Dodge GE, Donnelly J, Doughty D, Dragovitsch P, Dugger M, Dytman S, Dzyubak OP, Egiyan H, Elouadrhiri L, Empl A, Eugenio P, Fatemi R, Fedotov G, Feuerbach RJ, Forest TA, Funsten H, Gavalian G, Gevorgyan NG, Gilfoyle GP, Giovanetti KL, Girod FX, Goetz JT, Golovatch E, Gothe RW, Griffioen KA, Guidal M, Guillo M, Guler N, Guo L, Gyurjyan V, Hadjidakis C, Hardie J, Hersman FW, Hicks K, Hleiqawi I, Holtrop M, Hu J, Huertas M, Hyde-Wright CE, Ilieva Y, Ireland DG, Ishkhanov BS, Ito MM, Jenkins D, Jo HS, Joo K, Juengst HG, Kellie JD, Khandaker M, Kim KY, Kim K, Kim W, Klein A, Klein FJ, Klimenko A, Klusman M, Kramer LH, Kubarovsky V, Kuhn J, Kuhn SE, Kuleshov S, Lachniet J, Laget JM, Langheinrich J, Lawrence D, Lee T, Livingston K, Maximon LC, McAleer S, McKinnon B, McNabb JWC, Mecking BA, Mestayer MD, Meyer CA, Mibe T, Mikhailov K, Minehart R, Mirazita M, Miskimen R, Mokeev V, Morrow SA, Mueller J, Mutchler GS, Nadel-Turonski P, Napolitano J, Nasseripour R, Niccolai S, Niculescu G, Niculescu I, Niczyporuk BB, Niyazov RA, O'Relly GV, Osipenko M, Ostrovidov AI, Park K, Pasyuk E, Peterson C, Pierce J, Pivnyuk N, Pocanic D, Pogorelko O, Polli E, Pozdniakov S, Preedom BM, Price JW, Prok Y, Protopopescu D, Qin LM, Raue BA, Riccardi G, Ricco G, Ripani M, Ritchie BG, Ronchetti F, Rosner G, Rossi P, Rowntree D, Rubin PD, Sabatié F, Salgado C, Santoro JP, Sapunenko V, Schumacher RA, Serov VS, Sharabian YG, Shaw J, Smith ES, Smith LC, Sober DI, Stavinsky A, Stepanyan S, Stokes BE, Stoler P, Strauch S, Suleiman R, Taiuti M, Taylor S, Tedeschi DJ, Thompson R, Tkabladze A, Tkachenko S, Todor L, Tur C, Ungaro M, Vineyard MF, Vlassov AV, Weygand DP, Williams M, Wolin E, Wood MH, Yegneswaran A, Yun J, Zana L, Zhang J. Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett 2006; 96:082501. [PMID: 16606174 DOI: 10.1103/physrevlett.96.082501] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2005] [Indexed: 05/08/2023]
Abstract
The ratios of inclusive electron scattering cross sections of 4He, 12C, and 56Fe to 3He have been measured at 1 < xB <. At Q2 > 1.4 GeV2, the ratios exhibit two separate plateaus, at 1.5 < xB < 2 and at xB > 2.25. This pattern is predicted by models that include 2- and 3-nucleon short-range correlations (SRC). Relative to A = 3, the per-nucleon probabilities of 3-nucleon SRC are 2.3, 3.1, and 4.4 times larger for A = 4, 12, and 56. This is the first measurement of 3-nucleon SRC probabilities in nuclei.
Collapse
Affiliation(s)
- K S Egiyan
- Yerevan Physics Institute, Yerevan 375036, Armenia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|